Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 1

Conditions

Neoplasms 3Breast Neoplasms 2Solid Tumours 1Side-effect of Antibiotic 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Hodgkin Disease 1Carcinoma, Renal Cell 1Bacteremia 1Advanced Breast Cancer 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × Moxifloxacin × Clear all
NCT00861029 2017-11-14

VEG111485: A QTc Study of Pazopanib

GlaxoSmithKline

Phase 1 Completed
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT01874561 2016-10-10

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Achieve Life Sciences

Phase 1 Completed
155 enrolled
Tumor-Agnostic

Neoplasms

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡